Mark Hensley

Chairman at CALLIDITAS THERAPEUTICS AB

Net worth: 84 767 $ as of 31/07/2026

43 year

Health Technology

Consumer Services

Profile

Mark E.
Hensley is currently Chairman at Calliditas Therapeutics AB and Chief Operating Officer & Executive Vice President at Heron Therapeutics, Inc. starting in 2025.
Formerly, Mr. Hensley was Chief Commercial Officer at Veloxis Pharmaceuticals A from 2018 to 2021.
Education includes an undergraduate degree from the University of North Texas.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
HERON THERAPEUTICS INC 0.09%	06/08/2026	170,901 ( 0.09% )	84 767 $	31/07/2026

Mark Hensley active positions

Companies	Position	Start
CALLIDITAS THERAPEUTICS AB	Chairman	-
HERON THERAPEUTICS, INC.	Chief Operating Officer	28/04/2025

All active positions of Mark Hensley

Former positions of Mark Hensley

Companies	Position	End
VELOXIS PHARMACEUTICALS A/S	Corporate Officer/Principal	01/01/2021

See the detail of Mark Hensley's experience

Training of Mark Hensley

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Mark Hensley's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	4
Heron Therapeutics, Inc. Heron Therapeutics, Inc. BiotechnologyHealth Technology Manufactures and commercializes of polymer technologies	Health Technology
Veloxis Pharmaceuticals A/S Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for the prevention of organ rejection in kidney transplant patients	Health Technology
University of North Texas University of North Texas Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Calliditas Therapeutics AB Calliditas Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical products	Health Technology